Table 3.
Influence of sex and vaccine on geometric mean avidity levels over 4 months. The geometric mean avidity (GMA) levels were segregated by vaccine, time point and sex. Serum avidity increased significantly from months 1 to 4 in each group evaluated regardless of vaccine received. Males and females vaccinated with BNT162b2 or mRNA-1273 had similar avidity responses over the 4 months.
| Influence of Sex and Vaccine on Geometric Mean Avidity Levels Over 4 Months. | ||||||
|---|---|---|---|---|---|---|
| Vaccine | Sex at Birth | 1 Month | 4 Months | GM Fold Increase in Avidity | Sex at Birth× Time Interaction2 (p-value) |
|
| BNT162b2 | Female | n | 30 | 30 | 1.29* | .1754 |
| GMA (95% CI) | 3.8 (3.6–4.1) | 4.9 (4.6–5.3) | ||||
| Median (Q1, Q3) | 3.7 (3.4, 4.0) | 4.8 (4.5, 5.5) | ||||
| Male | n | 23 | 23 | 1.20* | ||
| GMA (95% CI) | 3.6 (3.9, 3.4) | 4.4 (4.0–4.7) | ||||
| Median (Q1, Q3) | 3.5 (3.4, 3.8) | 4.6 (3.8, 5.0) | ||||
| Female vs. Male | p-value1 | .3325 | .0607 | |||
| mRNA-1273 | Female | n | 26 | 26 | 1.20* | .3620 |
| GMA (95% CI) | 4.5 (4.2–4.8) | 5.4 (5.1–5.7) | ||||
| Median (Q1, Q3) | 4.3 (4.1, 4.9) | 5.5 (5.1, 5.9) | ||||
| Male | n | 23 | 23 | 1.14* | ||
| GMA (95% CI) | 4.6 (4.3–4.9) | 5.2 (5.0–5.5) | ||||
| Median (Q1, Q3) | 4.5 (4.2, 5.0) | 5.1 (4.9, 5.5) | ||||
| Female vs. Male | p-value1 | .7259 | .1520 | |||
*Significant increase in log avidity index, by signed-rank test (p < .0001).
1Rank-sum test.
2To test for a possible effect of sex at birth on the fold increase in avidity, a rank-sum test was applied to the 4 to 1 month change in log avidity index.